Toxometris.ai Integrates with eLabNext to Accelerate Toxicity Predictions and Drug Design

🕘 Zaven Navoyan	0	Performed 1	lests				
		Date		Text Name	Predicted Compounds	Status	Report File
Australia Terra		2023-04-04	Solubility		4	NUCCESS	d Ves
-		2023-04-24	Monnutieus is vitre		5	muccess.	# Ver
Performed Tests		2023-04-04	Herp Cardiotoxicity		3	8400888	d Vee
The New York	() ()	2023-04-24	Artes		5	BUCCEBB	d 1000
2. Personal Information		2023-04-23	Arres		16	0000888	d Vee
		2023-04-23	Solubility		71	BLOOPER	d Vee
Report Works		2023-04-23	Herg Cardioloxicity			success	d Vee
		2023-04-23	Micronactivas in vitro		54	muccene.	10 Vera
		2023-04-25	Herg Cardiotoxicity			1001455	d Ven
		2023-04-23	Solubility		11	94008999	d' Ven
Texametria.							

BOSTON, MA (October 2023) – Today, eLabNext, an Eppendorf Group Company offering a flexible, Al-powered Digital Laboratory Platform equipped with a Laboratory Inventory Management System (LIMS) and Electronic Lab Notebook (ELN), announced the inclusion of Toxometris.ai, an artificial intelligence (AI) tool that performs precise in silico toxicity and ADME property predictions of chemicals and substances, in eLabNext's add-on library, the eLabMarketplace.

The integration of the Toxometris.ai platform enables eLabNext users to access a powerful report on a chemical compounds' physicochemical, biological, and toxic activity in just a few clicks, reducing researchers' reliance on expensive and time-consuming wet lab testing in the early stages of pre-clinical drug development.

"Our vision has always been to replace experimental in vivo safety assessment methods experimental in vivo safety assessment methods with hybrid models that combine in silico and in vitro technologies to minimize the usage of animals for testing," says Zaven Navoyan, CEO of Toxometris.ai. "Making the Toxometris.ai platform available in the eLabNext software furthers this goal and enables researchers to easily prioritize their leads for further testing, derisk drug candidates, and ultimately, advance the safest and most effective drug products."





"Many eLabNext users are deeply entrenched in the pharmaceutical R&D, so we are always looking for techniques and technologies that make their jobs easier and more efficient," comments Zareh Zurabyan, Head of eLabNext, Americas. "As a platform that has long fostered laboratory digitalization, eLabNext has also been excited to adopt powerful AI tools that help users overcome global barriers, like the high failure rate and cost of small molecule drug development. Toxometris' shared interest in this issue has created a productive partnership with eLabNext, allowing us to offer our users a new technology for advancing promising drug candidates."

Currently, the Toxometris.ai add-on supports the following prediction endpoints: Genotoxicity, including AMES, in vitro micronucleus and in vivo micronucleus testing, aqueous solubility, hERG cardiotoxicity, rodent carcinogenicity, and hepatotoxicity predictions. The number of endpoints is constantly increasing and will eventually cover almost all absorption, distribution, metabolism, and excretion (ADME), and toxicity tests.

Toxon	netris.ai				
100		ound SMLES: curce	Chevenotecook	200	
10		ability demain status			
~ ()					
		enic activity: Non-Mu			
	Rule-b	ased prediction: Nor	Mutagenic		
	Value	type: Experimental			
Individual model sta notecular descriptors, Inc				largel compound accordin	g to models utilizin
		Prediction value		rediction confidence	
Statistical model usin	g descriptors	Non-Multin		.9	
Statistical model using	g fingerprints	Non-Mule	penic (592	
Graph neural network	model 1	Non-Mular	enic (.98	
Graph neural network	model 2	Non-Mulagenic		1.0	
Large language mode	0	Non-Muta	peric (0.81	
No alert found	No alert found	No alert found	No alert found	No alert found	No alert found
Top 6 negative alert arked according to their	Rund B: Snuchural alerts (S likelihood ratio (LR) are assad on the SA highlig	Tound A) associated with nor reported. Higher LR v fixed in red.	found mutagenic activity alues indicate the r	found (negative SA) found in the nore predictive accuracy fo	found target compound r a specific alert.
found Top 6 negative alert arked according to their	found R: Sinchural alerts (Sikelihood ratio (J.R) are	tound A) associated with non reported. Higher LR v	found mutagenic activity	found (negative SA) found in the	found
tourd Top 6 negative alert anked according to their take based prediction is t Geographic takes LE 16.00 Read-accross stedy:	Nound No. Shuchural alleris (S. Ria Sausid on the S.A. Right) No alort Sound Experimental values	Nound A) associated with non reported. Higher LR v has lon ed. No slott Round	Round mutagenic activity alues indicate the o Ne aliont found	Investigative SA) found in the consequence of the second o	found target compound r a specific alert. No dort found
tourd Top 6 negative alert anked according to their take based prediction is t Geographic takes LE 16.00 Read-accross stedy:	Nound No. Shuchural alleris (S. Ria Sausid on the S.A. Right) No alort Sound Experimental values	Nound A) associated with non reported. Higher LR v has lon ed. No slott Round	Round mutagenic activity alues indicate the o Ne aliont found	Investigative SA) found in the consequence of the second o	found target compound r a specific alert. No dort found
Top 6 negative alert arked according to their take based prediction is t of the based prediction is t the based prediction is t the based prediction is t	Nound No. Shuchural alleris (S. R.) Skelihoodraris (J. R.) are assed on the SA highlig No allert Sound Experimental values	Nound A) associated with non reported. Higher LR v has lon ed. No slott Round	Round mutagenic activity alues indicate the o Ne aliont found	Investigative SA) found in the consequence of the second o	found target compound r a specific alert. No dort found
tourd Top 6 negative alert anked according to their take based predictors at the based predictor at the based pred	No.nd N: Shucharal alteris (S. Balihood ratio (LR) an asaad on the SA Rejinij No alteri Ruand Experimental values o www.1 >= indix > 0.85 	Note that the second s	No alion No	Round In the social sector sec	found target compound r a specific alert. No dort found
tousd Top 6 negative alert anked according to their take based prediction is t	No.nd N: Shucharal alteris (S. Balihood ratio (LR) an asaad on the SA Rejinij No alteri Ruand Experimental values o www.1 >= indix > 0.85 	Sound A) associated with nor reported higher LR v have in not. No atort found f 3 nearest neighbors arrongly similar; index $\zeta = \zeta + \zeta + \zeta + \zeta$	Ibund mutagenic activity alues indicate the r No alort found tom the training se <= 0.85 low smilar	Round (negative SA) found in the none predictive accuracy for Round Round t are shown. The Dessitut compounds.	found target compound r a specific alert. No dort found


About Toxometris.ai


LEARN MORE

Toxometris.ai is a company that combines expertise from academic research labs focusing on in vitro and in vivo assessment of chemicals and an IT company specializing in different AI applications. Within the company, biologists and machine learning specialists work together to create cutting-edge AI models that predict the outcomes of toxicity assessment tests. Leveraging their collective experience, the team can develop highly accurate prediction models that help ensure the safety of chemicals and substances.









About eLabNext

eLabNext is an all-in-one Digital Lab Platform that offers an intuitive and flexible solution to collect, manage, and analyze laboratory information. The software includes modules for an electronic lab notebook, sample tracking, inventory management, and protocol management, as well as a wide range of marketplace add-ons to extend functionality. eLabNext enhances productivity by streamlining the processes of documenting, organizing, searching, and archiving data, samples, and protocols. The data is accessible through cloud-hosted ISO-certified data centers. The software is most suitable for industry R&D labs, ranging from start-up companies to mid-size pharma and biotech companies and academic research groups and institutes.



